Effects of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 on Overweight and the Gut Microbiota in Humans: Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Sung-Joon MoKippeum LeeHyoung-Ju HongDong-Ki HongSeung-Hee JungSoo-Dong ParkJae-Jung ShimJung-Lyoul LeePublished in: Nutrients (2022)
Obesity and overweight are closely related to diet, and the gut microbiota play an important role in body weight and human health. The aim of this study was to explore how Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 supplementation alleviate obesity by modulating the human gut microbiome. A randomized, double-blind, placebo-controlled study was conducted on 72 individuals with overweight. Over a 12-week period, probiotic groups consumed 1 × 10 10 colony-forming units of HY7601 and KY1032, whereas the placebo group consumed the same product without probiotics. After treatment, the probiotic group displayed a reduction in body weight ( p < 0.001), visceral fat mass ( p < 0.025), and waist circumference ( p < 0.007), and an increase in adiponectin ( p < 0.046), compared with the placebo group. Additionally, HY7601 and KY1032 supplementation modulated bacterial gut microbiota characteristics and beta diversity by increasing Bifidobacteriaceae and Akkermansiaceae and decreasing Prevotellaceae and Selenomonadaceae. In summary, HY7601 and KY1032 probiotics exert anti-obesity effects by regulating the gut microbiota; hence, they have therapeutic potential for preventing or alleviating obesity and living with overweight.
Keyphrases
- double blind
- weight loss
- placebo controlled
- body weight
- weight gain
- clinical trial
- insulin resistance
- phase iii
- body mass index
- metabolic syndrome
- phase ii
- human health
- type diabetes
- physical activity
- study protocol
- adipose tissue
- high fat diet induced
- risk assessment
- phase ii study
- open label
- skeletal muscle
- endothelial cells
- lactic acid
- signaling pathway
- locally advanced